CD8A and neoplasm: Some clinical trials for advanced malignancies have confirmed the potential of this approach to achieve prolonged remission in certain patients, although this required heavy lymphodepletion before T cell transfer [3], or engineering of CD8 T cells to improve tumour recognition [4].